Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00086203

Enrollment

Unknown

Registered

2004-06-29

Start date

Unknown

Completion date

2007-09-30

Last updated

2015-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphocytic Leukemia

Brief summary

The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.

Detailed description

Completion date provided represents the completion date of the grant per OOPD records

Interventions

DRUGTalabostat mesylate (PT-100) tablets

DRUGRituximab

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men or women ≥18 years of age * Histopathologically confirmed diagnosis of B-CLL expressing surface CD20 of any detectable intensity * Rai Stage III or IV. Rai Stages I and II with massive or progressive lymphadenopathy or hepatosplenomegaly. * Primary resistance to a fludarabine regimen (no PR or CR) or progressive disease within 1 year of a prior response * ECOG performance status 0, 1, or 2 * Written informed consent

Exclusion criteria

* Therapy for CLL within 4 weeks of Study Day 1 (including chemotherapy, radiation, immunotherapy, cytokine or biologic \[with the exception of hematopoietic growth factors\]). Patients must have recovered from the adverse effects of prior therapy. * Known primary or secondary malignancy of the central nervous system * Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix * Serum creatinine \>2.0mg/dL (\>176 micromol/L) * AST or ALT ≥3 x the upper limit of normal (ULN) * Total bilirubin ≥1.5 x ULN (unless secondary to Gilbert's) * Positive serology for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody) * Known positivity for HIV * Prior organ allograft * Concurrent comorbid medical conditions that, in the opinion of the investigator, preclude the safe delivery of the experimental treatment * Pregnant or nursing women

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026